Kenvue Inc (KVUE) Reports Mixed Full Year and Q4 Earnings Amidst Market Headwinds [Yahoo! Finance]
Kenvue Inc. (KVUE)
Company Research
Source: Yahoo! Finance
Full Year Diluted EPS : Reported at $0.90, with adjusted diluted EPS of $1.29. Q4 Diluted EPS : Reported at $0.17, with adjusted diluted EPS of $0.31. Gross Profit Margin : Improved in both full year and Q4, driven by value realization and supply chain efficiencies. 2024 Outlook : Kenvue forecasts full year 2024 net sales growth between 1.0% to 3.0% and organic growth between 2.0% to 4.0%. Adjusted Operating Income Margin : Expected to be slightly below 2023, with Adjusted diluted EPS in the range of $1.10 - $1.20. Warning! GuruFocus has detected 4 Warning Sign with KVUE. On February 8, 2024, Kenvue Inc ( NYSE:KVUE ) released its 8-K filing , detailing the financial results for the fiscal full year and fourth quarter ended December 31, 2023. Kenvue, known for its leading consumer health brands such as Tylenol and Neutrogena, faced a challenging quarter with a decline in net sales and organic growth, contrasting with a full year of growth. Company Overview Kenvue Inc (
Show less
Read more
Impact Snapshot
Event Time:
KVUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KVUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KVUE alerts
High impacting Kenvue Inc. news events
Weekly update
A roundup of the hottest topics
KVUE
News
- Kenvue Declares Quarterly Cash DividendBusiness Wire
- J&J Profit Beats Estimates as Pharma Sales Edge Out Street [BNN Bloomberg (Canada)]BNN Bloomberg
- Zimbabwe Recalls Tainted J&J's Cough Syrup Sold in Six African Nations [BNN Bloomberg (Canada)]BNN Bloomberg
- J&J's Tainted Cough Syrup Was Sold in Six African Countries [BNN Bloomberg (Canada)]BNN Bloomberg
- Kenvue Inc. (NYSE: KVUE) is now covered by analysts at Sanford C. Bernstein. They set an "underperform" rating and a $18.00 price target on the stock.MarketBeat
KVUE
Earnings
- 2/8/24 - Beat
KVUE
Sec Filings
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- 4/10/24 - Form DEF
- KVUE's page on the SEC website